Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This program is designed to study the efficacy, safety, lipid effects and tolerability of
raltegravir compared to lopinavir/ritonavir, in patients with HIV-I infection who have not
received prior antiretroviral therapy. All patients will receive concomitant therapy with
Truvada.